Acoltremon

Acoltremon (brand name TRYPTYR, formerly AR-15512) is a prescription eye drop approved by the FDA in 2025 for treating dry eye disease (DED) by acting as a TRPM8 receptor agonist, stimulating the production of natural tears and providing a cooling sensation, offering a novel approach distinct from traditional anti-inflammatory treatments for DED. Developed by Alcon, it's a first-in-class drug that works by activating cold-sensitive receptors on the cornea, leading to increased tear production and symptom relief, with effects seen as early as the first day